Automated Ex Vivo Compound Screening for Functional Precision Medicine

Dr. Maximilian Kramer-Drauberg, cbmed, Graz Automation is a key factor for translating functional precision oncology into clinically actionable workflows. We present a fully automated ex vivo compound screening platform designed for high‑throughput...

ELRIG-Forum 2026 Programm

Small Molecules and Biologics – from Lab to Data 08:00 08:45 Registration 08:50 09:00 Welcome by the ELRIG.de e.V. Richard Rösch 09:00 09:40 Targeted protein degradation & protein proximity – a journey from high throughput screening to developing drugs...

2026

Development of an antiviral RNAi inhalation drug for Human Parainfluenza Virus infection

Philippe-Vollmer-Barosa,Fraunhofer ITEM, Hannover Human Parainfluenza Virus is the second most abundant pathogen in viral respiratory infections in infants and also has major health implications on immunocompromised high-risk patients such as lung...

Human induced pluripotent stem cell-derived cardiomyocytes - Case studies for the application in early drug development

Ralf Kettenhofen, Ncardia, Köln, Germany Drug development projects in the pharma industry are focused on efficacy screening for the target of interest. But often compounds fail due to safety issues in costly late-stage safety pharmacological studies....